Answers are grounded in this paper and cite their sources.
In the current clinical scenario, people living with neuromuscular diseases (NMD) represent a vulnerable category with a high risk of severe course of COVID-19. Management of NMDs has become a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. This scoping review aims to bring forth crucial queries for general neurologists and specialists dealing with NMD patients in the time of COVID-19 and highlight the research areas in a novel pandemic situation.
No takes yet. Share an insight, caveat, or question.
Isha Akulwar-Tajane (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: